TY - JOUR
T1 - Giant prolactinomas
T2 - Case series and review of the literature
AU - Garla, Vishnu Vardhan
AU - Gosi, Shiva
AU - Palakodety, Sravanthi
AU - Kanduri, Swetha
AU - Kovvuru, Karthik
AU - Gunturu, Manasa
AU - Lien, Lillian
N1 - Publisher Copyright:
© The authors.
PY - 2020/12
Y1 - 2020/12
N2 - Giant prolactinomas are rare and constitute only 2-3% of prolactino-mas. They are defined as prolactinomas greater than 4 cm in size with a prolactin level of > 1,000 µg/L. Unlike prolactinomas, giant prol-actinomas have a male preponderance and present a decade earlier in men as compared to women. Giant prolactinomas may present with galactorrhea, irregular periods or decreased libido. Due to their large size, they can involve surrounding brain structures and may present with hydrocephalus, dizziness, seizures, deafness, and cognitive dys-function. Laboratory assessment may reveal a falsely low prolactin level secondary to “hook effect” which is due to saturation of the cap-ture and detection antibodies used in the assay. Dilution of the sample would show a paradoxical increase in prolactin levels confirming the hook effect. Magnetic resonance imaging (MRI) is warranted to as-sess the extent of the tumor. Dopamine agonists are the treatment of choice in giant prolactinomas and lead to rapid resolution of symp-toms, normalization of prolactin levels, and reduction in the size of the tumors. Refractory giant prolactinomas may be treated with surgery, temozolomide or radiotherapy. Giant prolactinomas can pose unique diagnostic and management challenges because of atypical presenta-tions and confounding laboratory assessments. We present four cases of giant prolactinomas each presenting in a unique manner and discuss the diagnostic and management dilemmas associated with them.
AB - Giant prolactinomas are rare and constitute only 2-3% of prolactino-mas. They are defined as prolactinomas greater than 4 cm in size with a prolactin level of > 1,000 µg/L. Unlike prolactinomas, giant prol-actinomas have a male preponderance and present a decade earlier in men as compared to women. Giant prolactinomas may present with galactorrhea, irregular periods or decreased libido. Due to their large size, they can involve surrounding brain structures and may present with hydrocephalus, dizziness, seizures, deafness, and cognitive dys-function. Laboratory assessment may reveal a falsely low prolactin level secondary to “hook effect” which is due to saturation of the cap-ture and detection antibodies used in the assay. Dilution of the sample would show a paradoxical increase in prolactin levels confirming the hook effect. Magnetic resonance imaging (MRI) is warranted to as-sess the extent of the tumor. Dopamine agonists are the treatment of choice in giant prolactinomas and lead to rapid resolution of symp-toms, normalization of prolactin levels, and reduction in the size of the tumors. Refractory giant prolactinomas may be treated with surgery, temozolomide or radiotherapy. Giant prolactinomas can pose unique diagnostic and management challenges because of atypical presenta-tions and confounding laboratory assessments. We present four cases of giant prolactinomas each presenting in a unique manner and discuss the diagnostic and management dilemmas associated with them.
KW - Giant prolactinoma
KW - Pituitary tumor
KW - Prolactinoma
UR - http://www.scopus.com/inward/record.url?scp=85098801196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098801196&partnerID=8YFLogxK
U2 - 10.14740/jem652
DO - 10.14740/jem652
M3 - Article
AN - SCOPUS:85098801196
SN - 1923-2861
VL - 10
SP - 182
EP - 189
JO - Journal of Endocrinology and Metabolism
JF - Journal of Endocrinology and Metabolism
IS - 6
ER -